Market Place
Sourcing Support
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
07 Mar 2024 //
BUSINESSWIRE
Ongoing Results From a Dose Expansion Cohort of CYT-0851
12 Oct 2023 //
BUSINESSWIRE
Cyteir calls it quits after months of cost cutting
30 Jun 2023 //
FIERCE BIOTECH
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program
30 Jun 2023 //
BUSINESSWIRE
Preliminary Result with CYT-0851 in Advanced Solid Tumors Show Clinical Activity
03 Jun 2023 //
BUSINESSWIRE
Fusion and Cyteir refocus pipelines; Nona collaborating with PharmaEssentia
12 May 2023 //
ENDPTS
Fusion, Cyteir refocus pipelines to funnel cash toward best bets
11 May 2023 //
FIERCE BIOTECH
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
23 Mar 2023 //
BUSINESSWIRE
Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer
06 Feb 2023 //
BUSINESSWIRE
Cyteir lets go of 35 staffers, goes all in on ovarian cancer
20 Jan 2023 //
ENDPTS
Cyteir Announces Prioritization of CYT-0851 Development & Extended Cash Runway
19 Jan 2023 //
BUSINESSWIRE
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results
07 Nov 2022 //
BUSINESSWIRE
Cyteir to Presents on the Identification of Mechanism of Action of CYT-0851
12 Oct 2022 //
BUSINESSWIRE
Cyteir to Participate in the Morgan Stanley Annual Global Healthcare Conference
31 Aug 2022 //
BUSINESSWIRE
Cyteir pauses development of cancer med
10 Aug 2022 //
FIERCEBIOTECH
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
BUSINESS WIRE
CYT-0851 PI Dose Escalation Results Show Early Clinical Activity in Solid Tumors
05 Jun 2022 //
BUSINESSWIRE
Cyteir Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
31 May 2022 //
BUSINESSWIRE
Cyteir Therapeutics Reports Q1 2022 Financial Results and Operational Highlights
05 May 2022 //
BUSINESSWIRE
Cyteir to Host Virtual Research and Development (R&D) Day on April 26, 2022
18 Apr 2022 //
BUSINESSWIRE
Cyteir Tx to Report Q4 and Full Year 2021 Financial Results on March 16, 2022
09 Mar 2022 //
BUSINESSWIRE
Cyteir Therapeutics Appoints Stephen Sands to Board of Directors
24 Feb 2022 //
BUSINESSWIRE
Cyteir Therapeutics Appoints John F. Thero to Board of Directors
07 Feb 2022 //
BUSINESSWIRE
Cyteir Tx Begins Dosing in Phase 1 Combination Trial With CYT-0851
12 Jan 2022 //
BUSINESSWIRE
Cyteir to Participate in the Annual Morgan Stanley Global Healthcare Conference
01 Sep 2021 //
BUSINESSWIRE
Cyteir Therapeutics to Participate in the 2021 Wedbush PacGrow Conference
02 Aug 2021 //
BUSINESS WIRE
Another four IPOs complete busy week as biotech raise continues to match 2020`s
18 Jun 2021 //
ENDPTS
Cyteir Therapeutics Announces Pricing of Initial Public Offering
17 Jun 2021 //
BUSINESSWIRE
Oncology biotech Cyteir Therapeutics sets terms for $126 million IPO
14 Jun 2021 //
RENAISSANCE CAPITAL
Cyteir Secures $80 Million in Series C Financing to Advance Clinical Trials
11 Feb 2021 //
PRNEWSWIRE
With crossover round in its pocket, synthetic lethality-focused Cyteir
11 Feb 2021 //
ENDPTS
Cyteir Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program
07 Jul 2020 //
PRNEWSWIRE
Cyteir Adds $40M for Clinical Test of “Synthetically Lethal” Cancer Drug
15 Oct 2019 //
XCONOMY
Bound for the clinic with a new approach to synthetic lethality, Cyteir $29M
08 Mar 2018 //
ENDPTS
